Related Experiment Video
Updated: May 6, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods
Ziyu Kuang1,2, Miao Kong1, Ningzhe Yan1,2
1Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Opinion Statement:
Cardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.
Insights
Omics approaches offer new ways to understand and diagnose cancer treatment-related cardiovascular toxicity (CTR-CVT). Integrating diverse omics data can personalize monitoring and treatment for cancer patients, improving cardiovascular outcomes.
Area of Science:
- Cardio-oncology
- Biomarker discovery
- Precision medicine
Background:
- Cardio-oncology addresses cardiovascular events during cancer treatment.
- Current management of cancer treatment-related cardiovascular toxicity (CTR-CVT) lacks detailed phenotypic data.
- Precision medicine and omics offer potential for diagnosing CTR-CVT.
Purpose of the Study:
- To review how omics approaches enhance CTR-CVT deep phenotyping.
- To discuss the pros and cons of omics for CTR-CVT diagnosis.
- To outline integrating multi-omics data for individualized patient care.
Main Methods:
- Review of current literature on omics methodologies in cardio-oncology.
- Analysis of deep phenotyping strategies for CTR-CVT.
- Discussion of multi-omics data integration techniques.
Main Results:
- Omics methodologies can significantly improve the understanding of CTR-CVT.
- Various omics approaches have distinct advantages and limitations for CTR-CVT diagnosis.
- Integrating multiple omics datasets is crucial for personalized monitoring and treatment.
Conclusions:
- Omics approaches are vital for advancing cardio-oncology and CTR-CVT management.
- Personalized monitoring and treatment strategies can be developed using integrated omics data.
- This approach promises to reduce cardiovascular complications in cancer patients and survivors.
More Related Videos
Related Concept Videos
02:02Genomics
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care